Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
InFo Hämatologie + Onkologie
Erschienen in: InFo Hämatologie + Onkologie 7-8/2021

27.07.2021 | Lymphome | Zertifizierte Fortbildung

PZNSL

Diagnostik und Therapie des primären ZNS-Lymphoms

verfasst von: Dr. med. Jens Blobner, Nico Teske, Dr. med. Philipp Karschnia, Prof. Dr. med. Martin Dreyling, PD. Dr. med Louisa von Baumgarten

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 7-8/2021

Einloggen, um Zugang zu erhalten

Auszug

Primäre ZNS-Lymphome sind hämatologische Neoplasien, die ausschließlich das zentrale Nervensystem befallen und aggressiv verlaufen. Ihre Seltenheit erschwert die systematische Bewertung und die Etablierung einheitlicher Behandlungsstandards. Trotz ihrer niedrigen Inzidenz befinden sich neuere Therapieansätze aktuell in der Erprobung. Lesen Sie in dieser Übersicht, worin diese neueren Konzepte bestehen - und wie PZNSL derzeit lege artis diagnostiziert und behandelt werden. …
Literatur
1.
Louis DN et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-20
2.
Ostrom QT et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. Neuro Oncol. 2018;20(suppl_4):iv1-iv86
3.
Matinella A et al. Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study. J Neurol. 2015;262(5):1317-27
4.
Küker W et al. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol. 2005;72(2):169-77
5.
Hoang-Xuan K et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol. 2015;16(7):e322-32
6.
Coulon A et al. Radiographic findings in 37 cases of primary CNS lymphoma in immunocompetent patients. Eur Radiol. 2002;12(2):329-40
7.
Bühring U et al. MRI features of primary central nervous system lymphomas at presentation. Neurology. 2001;57(3):393-6
8.
Deckert M et al. Primary lymphoma of the central nervous system--a diagnostic challenge. Hematol Oncol. 2014;32(2):57-67
9.
Grommes C et al. Comprehensive Approach to Diagnosis and Treatment of Newly Diagnosed Primary CNS Lymphoma. Neuro Oncol. 2019;21(3):296-305
10.
Weller M. Glucocorticoid treatment of primary CNS lymphoma. J Neurooncol. 1999;43(3):237-9
11.
Brück W et al. [Differential diagnosis of lymphoid infiltrates in the central nervous system: experience of the Network Lymphomas and Lymphomatoid Lesions in the Nervous System]. Pathologe. 2013;34(3):186-97
12.
Porter AB et al. Primary Central Nervous System Lymphoma Can Be Histologically Diagnosed after Previous Corticosteroid Use: A Pilot Study to Determine Whether Corticosteroids Prevent the Diagnosis of Primary Central Nervous System Lymphoma. Ann Neurol. 2008;63(5):662-7
13.
Ferreri AJM et al. How I Treat Primary CNS Lymphoma. Blood. 2011;118(3):510-22
14.
Jahnke K et al. Detection of Subclinical Systemic Disease in Primary CNS Lymphoma by Polymerase Chain Reaction of the Rearranged Immunoglobulin Heavy-Chain Genes. J Clin Oncol. 2006;24(29):4754-7
15.
Margold M et al. The Value of Bone Marrow Biopsy for Staging of Patients with Primary CNS Lymphoma. Neuro Oncol. 2021; https://​doi.​org/​10.​1093/​neuonc/​noab109
16.
Abrey LE et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034-43
17.
Mendez JS et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol. 2018;20(5):687-94
18.
Weller M et al. Surgery for Primary CNS Lymphoma? Challenging a Paradigm. Neuro Oncol. 2012;14(12):1481-4
19.
Herrlinger U et al. Neuro-Oncology Working Group of the German Society NOA-03 Trial of High-Dose Methotrexate in Primary Central Nervous System Lymphoma: Final Report. Ann Neurol. 2005;57(6):843-7
20.
Bergner N et al. Role of Chemotherapy Additional to High-Dose Methotrexate for Primary Central Nervous System Lymphoma (PCNSL). Cochrane Database Syst Rev. 2012;11:CD009355
21.
Ferreri AJM et al. High-Dose Cytarabine plus High-Dose Methotrexate versus High-Dose Methotrexate Alone in Patients with Primary CNS Lymphoma: A Randomised Phase 2 Trial. Lancet. 2009;374(9700):1512-20
22.
Pels H et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003;21(24):4489-95.
23.
Juergens A et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol. 2010;67(2):182-9
24.
Pels H et al. Early Relapses in Primary CNS Lymphoma after Response to Polychemotherapy without Intraventricular Treatment: Results of a Phase II Study. J Neurooncol. 2009;91(3):299-305
25.
Bromberg JEC et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2019;20(2):216-228
26.
Ferreri AJM et al. Chemoimmunotherapy with Methotrexate, Cytarabine, Thiotepa, and Rituximab (MATRix Regimen) in Patients with Primary CNS Lymphoma: Results of the First Randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) Phase 2 Trial. Lancet Haematol. 2016;3(5):e217-27
27.
Seidel S et al. Twenty-Year Follow-up of a Pilot/Phase II Trial on the Bonn Protocol for Primary CNS Lymphoma. Neurology. 2020;95(23):e3138-e3144
28.
Rubenstein JL et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31(25):3061-8
29.
Pulczynski EJ et al. Successful Change of Treatment Strategy in Elderly Patients with Primary Central Nervous System Lymphoma by De-Escalating Induction and Introducing Temozolomide Maintenance: Results from a Phase II Study by the Nordic Lymphoma Group. Haematologica. 2015;100(4):534-40
30.
Hoang-Xuan K et al. Chemotherapy Alone as Initial Treatment for Primary CNS Lymphoma in Patients Older than 60 Years: A Multicenter Phase II Study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol. 2003;21(14):2726-31
31.
Omuro A et al. Methotrexate and Temozolomide versus Methotrexate, Procarbazine, Vincristine, and Cytarabine for Primary CNS Lymphoma in an Elderly Population: An Intergroup ANOCEF-GOELAMS Randomised Phase 2 Trial. Lancet Haematol. 2015;2(6):e251-9
32.
Fritsch K et al. High-Dose Methotrexate-Based Immuno-Chemotherapy for Elderly Primary CNS Lymphoma Patients (PRIMAIN Study). Leukemia. 2017;31(4):846-52
33.
DeAngelis LM et al. Radiation Therapy Oncology Group Study 93-10 Combination Chemotherapy and Radiotherapy for Primary Central Nervous System Lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002;20(24):4643-8
34.
Poortmans PMP et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol. 2003;21(24):4483-8
35.
Korfel A et al. Response to Chemotherapy and Treating Institution Predict Survival in Primary Central Nervous System Lymphoma. Br J Haematol. 2005;128(2):177-83
36.
Thiel E et al. High-Dose Methotrexate with or without Whole Brain Radiotherapy for Primary CNS Lymphoma (G-PCNSL-SG-1): A Phase 3, Randomised, Non-Inferiority Trial. Lancet Oncol. 2010;11(11):1036-47
37.
Morris PG et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31(31):3971-9
38.
Glass J et al. Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. J Clin Oncol. 2016;34(14):1620-5
39.
Illerhaus G et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006;24(24):3865-70
40.
Kasenda B et al. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study. Ann Oncol. 2012;23(10):2670-5
41.
Omuro A et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403-10
42.
Illerhaus G et al. High-Dose Chemotherapy with Autologous Haemopoietic Stem Cell Transplantation for Newly Diagnosed Primary CNS Lymphoma: A Prospective, Single-Arm, Phase 2 Trial. Lancet Haematol. 2016;3(8):e388-97
43.
Ferreri AJM et al. Whole-Brain Radiotherapy or Autologous Stem-Cell Transplantation as Consolidation Strategies after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Primary CNS Lymphoma: Results of the Second Randomisation of the International Extranodal Lymphoma Study Group-32 Phase 2 Trial. Lancet Haematol. 2017;4(11):e510-e523
44.
Houillier C et al. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. J Clin Oncol. 2019;37(10):823-33
45.
von Baumgarten L et al. The Diagnosis and Treatment of Primary CNS Lymphoma. Dtsch Arztebl Int. 2018;115(25):419-26
46.
Löw S et al. Primary Central Nervous System Lymphoma. Ther Adv Neurol Disord. 2018;11:1756286418793562
47.
Nelson DF et al. Radiotherapy in the Treatment of Primary Central Nervous System Lymphoma (PCNSL). J Neurooncol. 1999;43(3):241-7
48.
DeAngelis LM et al. Primary CNS lymphoma: treatment with combined chemotherapy and radiotherapy. J Neurooncol. 1999;43(3):249-57
49.
DeAngelis LM et al. Combined Modality Therapy for Primary CNS Lymphoma. J Clin Oncol. 1992;10(4):635-43
50.
Glass J et al. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg. 1994;81(2):188-95
51.
O'Brien P et al. Phase II Multicenter Study of Brief Single-Agent Methotrexate Followed by Irradiation in Primary CNS Lymphoma. J Clin Oncol. 2000;18(3):519-26
52.
Abrey LE et al. Treatment for Primary CNS Lymphoma: The next Step. J Clin Oncol. 2000;18(17):3144-50
53.
Ferreri AJ et al. Combined Treatment with High-Dose Methotrexate, Vincristine and Procarbazine, without Intrathecal Chemotherapy, Followed by Consolidation Radiotherapy for Primary Central Nervous System Lymphoma in Immunocompetent Patients. Oncology. 2001;60(2):134-40
54.
Correa DD et al. Cognitive Functions in Primary CNS Lymphoma after Single or Combined Modality Regimens. Neuro Oncol. 2012;14(1):101-8
55.
Doolittle ND et al. Long-Term Cognitive Function, Neuroimaging, and Quality of Life in Primary CNS Lymphoma. Neurology. 2013;81(1):84-92
56.
Grommes C, DeAngelis LM. Primary CNS Lymphoma. J Clin Oncol. 2017;35(21):2410-8
57.
Schorb E et al. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix). BMC Cancer. 2016;16:282
58.
Langner-Lemercier S et al. Primary CNS Lymphoma at First Relapse/Progression: Characteristics, Management, and Outcome of 256 Patients from the French LOC Network. Neuro Oncol. 2016;18(9):1297-303
59.
Pentsova E et al. Methotrexate re-challenge for recurrent primary central nervous system lymphoma. J Neurooncol. 2014;117(1):161-5
60.
Plotkin SR et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res. 2004;10(17):5643-6
61.
Hottinger AF et al. Salvage Whole Brain Radiotherapy for Recurrent or Refractory Primary CNS Lymphoma. Neurology. 2007;69(11):1178-82
62.
Nguyen PL et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol. 2005;23(7):1507-13
63.
Kasenda B et al. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. Leukemia. 2017;31(12):2623-9
64.
Raizer JJ et al. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. Cancer. 2012;118(15):3743-8
65.
Fischer L et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol. 2006;17(7):1141-5
66.
Soussain C et al. Ibrutinib Monotherapy for Relapse or Refractory Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma: Final Analysis of the Phase II "proof-of-Concept" ILOC Study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network. Eur J Cancer. 2019;117:121-30
67.
Korfel A et al. Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma. J Clin Oncol. 2016;34(15):1757-63
68.
Rubenstein JL et al. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. 2018;2(13):1595-607
69.
Tun HW et al. Phase 1 Study of Pomalidomide and Dexamethasone for Relapsed/Refractory Primary CNS or Vitreoretinal Lymphoma. Blood. 2018;132(21):2240-8
70.
Ambady P et al. Combination Immunotherapy as a Non-Chemotherapy Alternative for Refractory or Recurrent CNS Lymphoma. Leuk Lymphoma. 2019;60(2):515-8
71.
Nayak L et al. PD-1 Blockade with Nivolumab in Relapsed/Refractory Primary Central Nervous System and Testicular Lymphoma. Blood. 2017;129(23):3071-3
72.
Abramson JS et al. Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma. N Engl J Med. 2017;377(8):783-4
73.
Ghesquieres H et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†. Ann Oncol. 2019;30(4):621-8
74.
Abrey LE et al. Long-Term Survival in Primary CNS Lymphoma. J Clin Oncol. 1998;16(3):859-63
75.
Kurzwelly D et al. Primary CNS Lymphoma in the Elderly: Temozolomide Therapy and MGMT Status. J Neurooncol. 2010;97(3):389-92
76.
Brandsma D et al. Primary CNS lymphoma in HIV infection. Handb Clin Neurol. 2018;152:177-186
77.
Wieters I et al. Autologous stem cell transplantation in HIV-related lymphoma in the rituximab era - a feasibility study in a monocentric cohort. J Int AIDS Soc. 2014;17(4 Suppl 3):19648
78.
Cavaliere R et al. International Primary Central Nervous System Lymphoma Collaborative Group Primary Central Nervous System Post-Transplantation Lymphoproliferative Disorder: An International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer. 2010;116(4):863-70
Metadaten
Titel
PZNSL
Diagnostik und Therapie des primären ZNS-Lymphoms
verfasst von
Dr. med. Jens Blobner
Nico Teske
Dr. med. Philipp Karschnia
Prof. Dr. med. Martin Dreyling
PD. Dr. med Louisa von Baumgarten
Publikationsdatum
27.07.2021
Verlag
Springer Medizin
Erschienen in
InFo Hämatologie + Onkologie / Ausgabe 7-8/2021
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI
https://doi.org/10.1007/s15004-021-8750-3

Weitere Artikel der Ausgabe 7-8/2021

InFo Hämatologie + Onkologie 7-8/2021 Zur Ausgabe

Editorial

Neues zu Diagnostik und Therapie

Info Pharm

Poteligeo® bremst Tumorprogression

Info Pharm

Tecartus® - Chance auf dauerhaftes Ansprechen

Neues aus der Forschung

Schlechte Impfantwort bei CLL-Patienten

Schwerpunkt

Prostatastanzbiopsie 2021: Wo stehen wir?*

Onkologie aktuell

CLL-Therapien auf dem Prüfstand

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise